FibroGen Company Profile (NASDAQ:FGEN)

About FibroGen (NASDAQ:FGEN)

FibroGen logoFibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FGEN
  • CUSIP: N/A
  • Web:
  • Market Cap: $4.16563 billion
  • Outstanding Shares: 71,195,000
Average Prices:
  • 50 Day Moving Avg: $44.39
  • 200 Day Moving Avg: $32.56
  • 52 Week Range: $15.60 - $53.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -35.67
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $117.9 million
  • Price / Sales: 32.31
  • Book Value: $3.24 per share
  • Price / Book: 16.51
  • EBIDTA: ($110,060,000.00)
  • Net Margins: -105.59%
  • Return on Equity: -64.42%
  • Return on Assets: -25.67%
  • Debt-to-Equity Ratio: 0.39%
  • Current Ratio: 6.21%
  • Quick Ratio: 6.21%
  • Average Volume: 865,009 shs.
  • Beta: 1.71
  • Short Ratio: 7.31

Frequently Asked Questions for FibroGen (NASDAQ:FGEN)

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen, Inc (NASDAQ:FGEN) issued its quarterly earnings data on Monday, August, 7th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.01. The business had revenue of $29 million for the quarter, compared to analysts' expectations of $34.80 million. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. View FibroGen's Earnings History.

When will FibroGen make its next earnings announcement?

FibroGen is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for FibroGen.

Where is FibroGen's stock going? Where will FibroGen's stock price be in 2017?

7 analysts have issued twelve-month price targets for FibroGen's stock. Their forecasts range from $31.00 to $82.00. On average, they expect FibroGen's stock price to reach $66.60 in the next twelve months. View Analyst Ratings for FibroGen.

Who are some of FibroGen's key competitors?

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:

  • Thomas B. Neff, Chairman of the Board, Chief Executive Officer, Founder
  • Pat Cotroneo, Chief Financial Officer, Vice President - Finance
  • Frank H. Valone M.D., Senior Fellow, Clinical Development
  • K. Peony Yu M.D., Chief Medical Officer
  • Jeffrey L. Edwards, Independent Director
  • Jeffrey William Henderson, Independent Director
  • Thomas F. Kearns Jr., Independent Director
  • Kalevi Kurkijarvi Ph.D., Independent Director
  • Rory B. Riggs, Independent Director

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who owns FibroGen stock?

FibroGen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.30%), BlackRock Inc. (7.15%), FMR LLC (4.77%), State Street Corp (2.48%), Hillhouse Capital Management Ltd. (2.46%) and EcoR1 Capital LLC (2.23%). Company insiders that own FibroGen stock include Frank H Md Valone, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Miguel Madero, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr, Thomas F Kearns, Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

Who sold FibroGen stock? Who is selling FibroGen stock?

FibroGen's stock was sold by a variety of institutional investors in the last quarter, including Omega Fund Management LLC, Acadian Asset Management LLC, JPMorgan Chase & Co., Candriam Luxembourg S.C.A., Castleark Management LLC, Pinnacle Associates Ltd., Capital Impact Advisors LLC and Royal Bank of Canada. Company insiders that have sold FibroGen stock in the last year include Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Insider Buying and Selling for FibroGen.

Who bought FibroGen stock? Who is buying FibroGen stock?

FibroGen's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, EcoR1 Capital LLC, Janus Henderson Group PLC, Vanguard Group Inc., Hillhouse Capital Management Ltd., BlackRock Inc., Farallon Capital Management LLC and State Street Corp. View Insider Buying and Selling for FibroGen.

How do I buy FibroGen stock?

Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FibroGen stock can currently be purchased for approximately $53.50.

MarketBeat Community Rating for FibroGen (NASDAQ FGEN)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  123 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for FibroGen (NASDAQ:FGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $66.60 (24.49% upside)

Analysts' Ratings History for FibroGen (NASDAQ:FGEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/14/2017Stifel NicolausReiterated RatingBuy$80.00LowView Rating Details
9/12/2017Jefferies Group LLCReiterated RatingBuy$75.00LowView Rating Details
8/9/2017William BlairReiterated RatingOutperformMediumView Rating Details
8/8/2017Leerink SwannReiterated RatingOutperform -> Outperform$52.00 -> $82.00HighView Rating Details
8/8/2017Citigroup Inc.Boost Price TargetTop Pick$48.00 -> $65.00HighView Rating Details
7/21/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$31.00MediumView Rating Details
1/18/2017Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
8/9/2016Credit Suisse GroupReiterated RatingBuy$37.00N/AView Rating Details
9/23/2015Lake Street CapitalInitiated CoverageHold$25.00N/AView Rating Details
(Data available from 9/20/2015 forward)


Earnings History for FibroGen (NASDAQ:FGEN)
Earnings by Quarter for FibroGen (NASDAQ:FGEN)
Earnings History by Quarter for FibroGen (NASDAQ FGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.36)N/AView Earnings Details
8/7/2017Q2 2017($0.47)($0.48)$34.80 million$29.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.63)($0.52)$26.02 million$26.89 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.53)($0.54)$19.29 million$31.91 millionViewListenView Earnings Details
11/8/2016Q3($0.63)($0.38)$24.30 million$30.10 millionViewListenView Earnings Details
8/8/2016Q2$0.36$0.35$80.58 million$89.28 millionViewListenView Earnings Details
5/9/2016Q116($0.56)($0.45)$16.89 million$28.28 millionViewListenView Earnings Details
2/29/2016Q4($0.54)($0.85)$40.44 million$24.44 millionViewListenView Earnings Details
11/12/2015Q3($0.61)($0.74)$28.74 million$19.54 millionViewListenView Earnings Details
8/13/2015Q215$0.73$0.83$111.75 million$120.55 millionViewListenView Earnings Details
5/12/2015Q115($0.53)($0.78)$34.00 million$16.30 millionViewN/AView Earnings Details
3/26/2015Q414($0.90)($0.82)$16.49 million$16.11 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for FibroGen (NASDAQ:FGEN)
2017 EPS Consensus Estimate: ($2.05)
2018 EPS Consensus Estimate: ($1.17)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.77)($0.48)($0.63)
Q2 20173($0.47)($0.43)($0.45)
Q3 20173($0.49)($0.23)($0.39)
Q4 20173($0.69)($0.49)($0.59)
Q1 20181($0.72)($0.72)($0.72)
Q2 20181($0.69)($0.69)($0.69)
Q3 20181$0.86$0.86$0.86
Q4 20181($0.62)($0.62)($0.62)
(Data provided by Zacks Investment Research)


Dividend History for FibroGen (NASDAQ:FGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for FibroGen (NASDAQ:FGEN)
Insider Ownership Percentage: 14.90%
Institutional Ownership Percentage: 47.49%
Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)
Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)
Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2017K Peony YuInsiderSell2,851$51.00$145,401.00View SEC Filing  
9/14/2017Thomas B NeffCEOSell38,636$51.67$1,996,322.12View SEC Filing  
9/13/2017Rory B RiggsDirectorSell25,000$51.92$1,298,000.00View SEC Filing  
9/13/2017Thomas B NeffCEOSell18,900$51.29$969,381.00View SEC Filing  
9/11/2017Pat CotroneoVPSell2,851$49.45$140,981.95View SEC Filing  
9/1/2017Jorma RouttiDirectorSell12,000$47.36$568,320.00View SEC Filing  
8/29/2017Thomas B NeffCEOSell38,636$43.73$1,689,552.28View SEC Filing  
8/28/2017Thomas B NeffCEOSell18,900$43.04$813,456.00View SEC Filing  
8/21/2017K Peony YuInsiderSell7,500$41.03$307,725.00View SEC Filing  
8/8/2017K Peony YuInsiderSell37,500$50.58$1,896,750.00View SEC Filing  
8/8/2017Pat CotroneoVPSell95,000$50.61$4,807,950.00View SEC Filing  
8/2/2017Pat CotroneoVPSell28,346$33.97$962,913.62View SEC Filing  
8/1/2017K Peony YuInsiderSell10,000$33.48$334,800.00View SEC Filing  
7/25/2017Thomas B NeffCEOSell38,636$35.09$1,355,737.24View SEC Filing  
7/24/2017Thomas B NeffCEOSell18,900$35.06$662,634.00View SEC Filing  
7/17/2017Kalevi KurkijarviDirectorSell2,000$33.45$66,900.00View SEC Filing  
7/10/2017K Peony YuInsiderSell5,000$32.98$164,900.00View SEC Filing  
7/7/2017Thomas B NeffCEOSell38,636$33.38$1,289,669.68View SEC Filing  
7/6/2017Pat CotroneoVPSell4,000$34.00$136,000.00View SEC Filing  
7/6/2017Thomas B NeffCEOSell18,900$33.53$633,717.00View SEC Filing  
6/22/2017Pat CotroneoVPSell3,000$32.00$96,000.00View SEC Filing  
6/22/2017Thomas B NeffCEOSell38,636$31.52$1,217,806.72View SEC Filing  
6/19/2017Pat CotroneoVPSell5,500$30.00$165,000.00View SEC Filing  
6/16/2017Thomas B NeffCEOSell38,636$29.40$1,135,898.40View SEC Filing  
6/15/2017Kalevi KurkijarviDirectorSell2,000$28.50$57,000.00View SEC Filing  
6/14/2017K Peony YuInsiderSell3,721$28.95$107,722.95View SEC Filing  
6/12/2017Pat CotroneoVPSell2,891$28.75$83,116.25View SEC Filing  
6/12/2017Toshinari TamuraDirectorSell30,000$28.89$866,700.00View SEC Filing  
6/6/2017Thomas F Kearns JrDirectorSell18,000$28.71$516,780.00View SEC Filing  
5/31/2017Thomas B NeffCEOSell38,636$26.21$1,012,649.56View SEC Filing  
5/16/2017Kalevi KurkijarviDirectorSell2,000$27.40$54,800.00View SEC Filing  
5/16/2017Thomas B NeffCEOSell38,636$27.70$1,070,217.20View SEC Filing  
5/15/2017Thomas B NeffCEOSell18,900$27.75$524,475.00View SEC Filing  
5/10/2017K Peony YuInsiderSell5,000$26.38$131,900.00View SEC Filing  
4/25/2017K Peony YuInsiderSell5,000$28.00$140,000.00View SEC Filing  
4/25/2017Pat CotroneoVPSell6,500$28.00$182,000.00View SEC Filing  
4/25/2017Thomas B NeffCEOSell38,636$26.92$1,040,081.12View SEC Filing  
4/24/2017Thomas B NeffCEOSell18,900$26.35$498,015.00View SEC Filing  
4/17/2017Kalevi KurkijarviDirectorSell2,000$25.25$50,500.00View SEC Filing  
4/13/2017Thomas B NeffCEOSell38,636$24.79$957,786.44View SEC Filing  
4/4/2017Thomas B NeffCEOSell38,636$23.92$924,173.12View SEC Filing  
3/21/2017Thomas B NeffCEOSell38,636$24.34$940,400.24View SEC Filing  
3/20/2017Thomas B NeffCEOSell18,900$24.88$470,232.00View SEC Filing  
3/15/2017Thomas B NeffCEOSell38,636$25.07$968,604.52View SEC Filing  
2/16/2017Kalevi KurkijarviDirectorSell2,000$24.45$48,900.00View SEC Filing  
2/14/2017Thomas B NeffCEOSell38,636$23.94$924,945.84View SEC Filing  
2/13/2017Thomas B NeffCEOSell18,900$23.97$453,033.00View SEC Filing  
2/9/2017Thomas B NeffCEOSell37,798$23.46$886,741.08View SEC Filing  
1/27/2017Thomas B NeffCEOSell37,798$23.29$880,315.42View SEC Filing  
1/19/2017Kalevi KurkijarviDirectorSell2,000$24.90$49,800.00View SEC Filing  
1/12/2017Thomas B NeffCEOSell37,798$23.85$901,482.30View SEC Filing  
1/11/2017Pat CotroneoVPSell6,500$24.00$156,000.00View SEC Filing  
1/10/2017K Peony YuInsiderSell5,000$23.56$117,800.00View SEC Filing  
12/28/2016Thomas B NeffCEOSell37,798$20.74$783,930.52View SEC Filing  
12/16/2016Rory B RiggsDirectorSell20,000$20.87$417,400.00View SEC Filing  
12/13/2016Thomas B NeffCEOSell37,798$21.24$802,829.52View SEC Filing  
12/12/2016Pat CotroneoVPSell2,344$22.05$51,685.20View SEC Filing  
12/12/2016Thomas B NeffCEOSell18,899$21.48$405,950.52View SEC Filing  
11/29/2016Thomas B NeffCEOSell37,798$22.80$861,794.40View SEC Filing  
11/28/2016Thomas B NeffCEOSell18,899$22.74$429,763.26View SEC Filing  
11/18/2016Thomas F Kearns JrDirectorSell18,000$22.40$403,200.00View SEC Filing  
11/17/2016Thomas B NeffCEOSell37,798$22.29$842,517.42View SEC Filing  
11/1/2016Thomas B NeffCEOSell37,798$16.76$633,494.48View SEC Filing  
10/19/2016Thomas B NeffCEOSell37,798$17.75$670,914.50View SEC Filing  
10/18/2016Thomas B NeffCEOSell18,899$17.94$339,048.06View SEC Filing  
10/4/2016Thomas B NeffCEOSell18,899$20.67$390,642.33View SEC Filing  
10/3/2016Thomas B NeffCEOSell18,899$20.55$388,374.45View SEC Filing  
9/21/2016Thomas B NeffCEOSell37,798$21.66$818,704.68View SEC Filing  
9/14/2016K Peony YuInsiderSell2,345$18.66$43,757.70View SEC Filing  
9/12/2016Pat CotroneoVPSell2,345$18.22$42,725.90View SEC Filing  
9/9/2016Thomas B NeffCEOSell37,798$18.99$717,784.02View SEC Filing  
8/26/2016Thomas B NeffCEOSell37,798$17.80$672,804.40View SEC Filing  
7/27/2016Thomas B NeffCEOSell37,798$18.38$694,727.24View SEC Filing  
7/13/2016Thomas B NeffCEOSell27,000$17.50$472,500.00View SEC Filing  
6/29/2016Thomas B NeffCEOSell27,000$16.02$432,540.00View SEC Filing  
6/15/2016Pat CotroneoCFOSell1,796$16.49$29,616.04View SEC Filing  
6/15/2016Thomas B NeffCEOSell27,000$16.48$444,960.00View SEC Filing  
6/10/2016K Peony YuInsiderSell2,344$17.96$42,098.24View SEC Filing  
6/3/2016Thomas B NeffCEOSell27,000$18.99$512,730.00View SEC Filing  
5/20/2016Thomas B NeffCEOSell27,000$17.68$477,360.00View SEC Filing  
5/16/2016Pat CotroneoCFOSell6,107$17.60$107,483.20View SEC Filing  
5/3/2016Thomas B NeffCEOSell27,000$17.78$480,060.00View SEC Filing  
4/20/2016Thomas B NeffCEOSell27,000$19.98$539,460.00View SEC Filing  
4/19/2016Thomas B NeffCEOSell13,500$20.21$272,835.00View SEC Filing  
4/5/2016Thomas B NeffCEOSell27,000$21.11$569,970.00View SEC Filing  
4/1/2016Frank H Md ValoneInsiderSell10,750$21.11$226,932.50View SEC Filing  
3/22/2016Thomas B NeffCEOSell27,000$18.74$505,980.00View SEC Filing  
3/8/2016Thomas B NeffCEOSell27,000$19.62$529,740.00View SEC Filing  
3/1/2016Frank H Md ValoneInsiderSell10,750$16.84$181,030.00View SEC Filing  
2/23/2016Thomas B NeffCEOSell27,000$19.11$515,970.00View SEC Filing  
2/22/2016Thomas B NeffCEOSell13,500$19.81$267,435.00View SEC Filing  
2/16/2016Frank H. Md ValoneinsiderSell10,750$18.41$197,907.50View SEC Filing  
2/10/2016Thomas B. NeffCEOSell27,000$15.31$413,370.00View SEC Filing  
1/29/2016Thomas B. NeffCEOSell27,000$19.41$524,070.00View SEC Filing  
1/21/2016Thomas F Kearns JrDirectorSell1,572$22.08$34,709.76View SEC Filing  
1/14/2016Thomas B. NeffCEOSell27,000$23.69$639,630.00View SEC Filing  
12/24/2015Thomas F. Kearns, Jr.DirectorSell7,800$30.88$240,864.00View SEC Filing  
12/23/2015Thomas B. NeffCEOSell27,000$30.10$812,700.00View SEC Filing  
12/11/2015Thomas B. NeffCEOSell27,000$29.59$798,930.00View SEC Filing  
12/10/2015K Peony YuVPSell1,093$28.96$31,653.28View SEC Filing  
12/8/2015Miguel MaderoDirectorSell40,386$30.49$1,231,369.14View SEC Filing  
11/30/2015K Peony YuVPSell5,000$30.00$150,000.00View SEC Filing  
11/25/2015Pat CotroneoCFOSell5,000$30.00$150,000.00View SEC Filing  
11/24/2015Thomas B. NeffCEOSell13,500$28.98$391,230.00View SEC Filing  
11/24/2015Thomas F. Kearns, Jr.DirectorSell3,900$29.00$113,100.00View SEC Filing  
11/23/2015Thomas B. NeffCEOSell13,500$27.99$377,865.00View SEC Filing  
11/23/2015Thomas F. Kearns, Jr.DirectorSell3,900$28.02$109,278.00View SEC Filing  
11/17/2015K Peony YuVPSell5,000$28.00$140,000.00View SEC Filing  
11/10/2015K Peony YuVPSell5,000$25.62$128,100.00View SEC Filing  
11/9/2015K Peony YuVPSell2,500$25.00$62,500.00View SEC Filing  
11/2/2015Frank H. Md ValoneinsiderSell10,000$23.18$231,800.00View SEC Filing  
10/30/2015Thomas B. NeffCEOSell27,000$24.06$649,620.00View SEC Filing  
10/21/2015Thomas F. Kearns, Jr.DirectorSell7,800$23.83$185,874.00View SEC Filing  
10/19/2015Frank H. Md ValoneinsiderSell10,000$23.00$230,000.00View SEC Filing  
10/19/2015K Peony YuVPSell5,000$24.00$120,000.00View SEC Filing  
10/16/2015K Peony YuVPSell5,000$21.46$107,300.00View SEC Filing  
10/16/2015Thomas B. NeffCEOSell27,000$21.86$590,220.00View SEC Filing  
10/2/2015Thomas B. NeffCEOSell27,000$21.59$582,930.00View SEC Filing  
10/1/2015Frank H. Md ValoneinsiderSell10,000$21.38$213,800.00View SEC Filing  
9/18/2015Thomas B. NeffCEOSell27,000$29.10$785,700.00View SEC Filing  
9/15/2015Pat CotroneoCFOSell1,093$27.95$30,549.35View SEC Filing  
9/14/2015Rory B. RiggsDirectorSell50,000$27.61$1,380,500.00View SEC Filing  
9/11/2015Miguel MaderoDirectorSell20,600$27.66$569,796.00View SEC Filing  
9/10/2015K Peony YuVPSell1,093$27.84$30,429.12View SEC Filing  
9/10/2015Pat CotroneoCFOSell7,500$27.33$204,975.00View SEC Filing  
9/4/2015Thomas B. NeffCEOSell13,500$22.88$308,880.00View SEC Filing  
9/3/2015Thomas B. NeffCEOSell13,500$22.92$309,420.00View SEC Filing  
9/1/2015Frank H. Md ValoneinsiderSell10,000$23.58$235,800.00View SEC Filing  
7/23/2015Thomas B NeffCEOSell27,000$24.71$667,170.00View SEC Filing  
7/20/2015Frank H Md ValoneInsiderSell1,000$23.70$23,700.00View SEC Filing  
7/20/2015Pat CotroneoCFOSell7,881$23.47$184,967.07View SEC Filing  
7/9/2015Thomas B NeffCEOSell27,000$22.11$596,970.00View SEC Filing  
7/6/2015K Peony YuVPSell5,381$22.69$122,094.89View SEC Filing  
6/25/2015Thomas B NeffCEOSell27,000$23.57$636,390.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for FibroGen (NASDAQ:FGEN)
Latest Headlines for FibroGen (NASDAQ:FGEN)
DateHeadline logoFibroGen Appoints Gerald Lema to Board of Directors - GlobeNewswire (press release) - September 19 at 11:40 PM logoFibroGen Appoints Gerald Lema to Board of Directors - September 19 at 6:37 PM logoFibroGen, Inc (FGEN) Given Buy Rating at Jefferies Group LLC - September 17 at 8:58 PM logoK Peony Yu Sells 2,851 Shares of FibroGen, Inc (FGEN) Stock - September 15 at 8:03 PM logoThomas B. Neff Sells 38,636 Shares of FibroGen, Inc (FGEN) Stock - September 15 at 7:24 PM logoThomas B. Neff Sells 18,900 Shares of FibroGen, Inc (FGEN) Stock - September 15 at 7:24 PM logoFibroGen, Inc (FGEN) Director Sells $1,298,000.00 in Stock - September 15 at 7:24 PM logoFY2019 Earnings Estimate for FibroGen, Inc Issued By William Blair (FGEN) - September 15 at 4:14 PM logoFibroGen, Inc (FGEN) Earns "Buy" Rating from Stifel Nicolaus - September 14 at 1:04 PM logoFibroGen, Inc (FGEN) Expected to Announce Quarterly Sales of $41.34 Million - September 14 at 8:20 AM logoFibroGen (FGEN) Reports Latest Data From Phase 2b Study of ... - - September 14 at 1:05 AM logoFibroGen, Inc (FGEN) VP Pat Cotroneo Sells 2,851 Shares - September 13 at 8:30 PM logoFibroGen (FGEN) Reports Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis - September 13 at 8:03 PM logoFibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic ... - September 13 at 8:03 PM logoFibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society (ERS) International Congress 2017 - September 13 at 8:03 PM logoFibroGen, Inc (FGEN) Receives Consensus Recommendation of "Buy" from Brokerages - September 9 at 2:54 AM logoIs There Now An Opportunity In FibroGen Inc (FGEN)? - September 6 at 11:35 PM logoJorma Routti Sells 12,000 Shares of FibroGen, Inc (FGEN) Stock - September 5 at 10:26 PM logoFibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017 - September 5 at 8:27 PM logoAnalysts See 11% Upside For The Holdings of VBK - August 31 at 6:33 PM logoFibroGen, Inc (FGEN) CEO Thomas B. Neff Sells 38,636 Shares - August 30 at 10:20 PM logoK Peony Yu Sells 7,500 Shares of FibroGen, Inc (FGEN) Stock - August 23 at 7:46 PM logoFibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock - Nasdaq - August 17 at 4:47 AM logoFibroGen Prices Follow-On Offering - August 16 at 11:44 PM logoPre-Market Most Active for Aug 16, 2017 : TGT, FCAU, TEVA, NEFF, URBN, BABA, YY, FGEN, AAPL, TVIX, SNAP, QQQ - Nasdaq - August 16 at 6:43 PM logoFibroGen, Inc. Announces Proposed Follow-On Offering of Common Stock - GlobeNewswire (press release) - August 15 at 5:03 AM logoFibroGen, Inc (FGEN) Receives Consensus Rating of "Buy" from Brokerages - August 15 at 2:56 AM logoFibroGen, Inc. Announces Proposed Follow-On Offering of Common Stock - August 14 at 6:59 PM logoSee what the IHS Markit Score report has to say about FibroGen Inc. - August 12 at 5:54 PM logoFibroGen, Inc (NASDAQ:FGEN) Insider K Peony Yu Sells 37,500 Shares - August 10 at 10:38 PM logoFibroGen, Inc (NASDAQ:FGEN) VP Pat Cotroneo Sells 95,000 Shares - August 10 at 10:38 PM logoQ3 2017 Earnings Estimate for FibroGen, Inc (NASDAQ:FGEN) Issued By Jefferies Group - August 10 at 11:56 AM logoQ3 2017 EPS Estimates for FibroGen, Inc (NASDAQ:FGEN) Increased by William Blair - August 10 at 7:06 AM logoLeerink Swann Analysts Lower Earnings Estimates for FibroGen, Inc (NASDAQ:FGEN) - August 10 at 7:06 AM logoFibroGen Inc. (FGEN) Leaped To A New High On Phase 2 Study Results - August 10 at 4:57 AM logoStrength Seen in FibroGen (FGEN): Stock Soars 48.2% - Nasdaq - August 9 at 11:54 PM logoFibroGen Reaches Analyst Target Price - Nasdaq - August 9 at 6:51 PM logoWilliam Blair Weighs in on FibroGen, Inc's Q3 2018 Earnings (FGEN) - August 9 at 1:30 PM logoFibroGen Inc. (FGEN) Has Soared To A New High On Phase 2 Study News - August 8 at 11:26 PM logoEdited Transcript of FGEN earnings conference call or presentation 7-Aug-17 9:00pm GMT - August 8 at 11:26 PM logoFibroGen shares surge 49% on positive mid-stage trial for pulmonary fibrosis therapy - August 8 at 11:25 PM logoWhy Fibrogen Shares Are Exploding - August 8 at 11:25 PM logoBUZZ-US STOCKS ON THE MOVE-Valeant, Michael Kors, FibroGen, Ralph Lauren - Nasdaq - August 8 at 6:24 PM logoBUZZ-US STOCKS ON THE MOVE-Michael Kors, Ralph Lauren, Gartner, FibroGen - Nasdaq - August 8 at 6:24 PM logoFibroGen shares surge 49% on positive mid-stage trial for pulmonary fibrosis therapy - MarketWatch - August 8 at 6:24 PM logoWhy Fibrogen Shares Are Exploding - 24/7 Wall St. - August 8 at 6:24 PM logoWhy Did FibroGen (FGEN) Stock Hit All-Time High Today? - August 8 at 6:24 PM logoWhy Ralph Lauren, LendingClub, and FibroGen Jumped Today - August 8 at 6:24 PM logoFibroGen, Inc (NASDAQ:FGEN) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - August 8 at 12:46 PM logoFibroGen, Inc (FGEN) Earns Positive Rating from Leerink Swann - August 8 at 9:32 AM



FibroGen (FGEN) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff